Company Overview - Jingxin Pharmaceutical (002020.SZ) is an innovation-driven pharmaceutical group focusing on two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases. The company combines the commercialization of existing products with the continuous advancement of its product pipeline [1] - The company has shifted its strategic focus on innovative drug development towards central nervous system diseases and cardiovascular and cerebrovascular diseases, with a product portfolio that includes over 60 approved drugs, covering generic drugs, innovative drugs, traditional Chinese medicine, and biological agents [2] Financial Performance - For the fiscal years ending December 31, 2023, 2024, and the ten months ending October 31, 2025, the company reported revenues of approximately RMB 3.999 billion, RMB 4.159 billion, and RMB 3.344 billion, respectively [5] - The net profit for the same periods was approximately RMB 623 million, RMB 719 million, and RMB 629 million [4] - The gross profit margins for the fiscal years were 49.2%, 48.5%, and 48.3% respectively [6] Product Segmentation - The revenue breakdown by business line for 2023 shows that the main sources of income are from the following segments: - Pharmaceuticals: RMB 2.326 billion (58.2%) - Network: RMB 956 million (23.9%) - Medical devices: RMB 637 million (16.0%) [2] Market Overview - The Chinese pharmaceutical market is projected to grow from RMB 1,447.9 billion in 2020 to RMB 1,629.7 billion by 2024, with a compound annual growth rate (CAGR) of 3.0%. By 2035, it is expected to reach RMB 3,103.4 billion, with a CAGR of 6.5% from 2025 to 2035, surpassing the global CAGR of 5.1% during the same period [8] - The market share of patented drugs is expected to increase from 44.6% in 2020 to 70.0% by 2035, while the market share of generic drugs will decline from 55.4% to 30.0% [8] Central Nervous System Market - The global central nervous system drug market is expected to grow from USD 233.7 billion in 2020 to USD 258.8 billion by 2024, with a CAGR of 2.6%. The Chinese market is projected to grow from approximately USD 32.2 billion in 2020 to USD 34.1 billion by 2024, with a CAGR of 1.4% [10] - The insomnia drug market in China is expected to maintain a size of around USD 1.7 billion from 2020 to 2024, with a CAGR of -1.0%. However, it is projected to grow to USD 3.5 billion by 2035, with a CAGR of 7.5% from 2025 to 2035 [12] Cardiovascular Market - The global cardiovascular drug market is expected to grow from USD 115 billion in 2020 to USD 124.6 billion by 2024, with a CAGR of 2.0%. It is projected to reach USD 182 billion by 2035, with a CAGR of 3.8% from 2025 to 2035 [13] - The Chinese cardiovascular drug market is expected to decline from USD 25.5 billion in 2020 to USD 24.9 billion by 2024, with a CAGR of -0.7%. However, it is anticipated to rebound to USD 36.9 billion by 2035, with a CAGR of 4.1% from 2025 to 2035 [13]

Company Overview - Jingxin Pharmaceutical (002020.SZ) is an innovation-driven pharmaceutical group focusing on two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases. The company combines the commercialization of existing products with the continuous advancement of its product pipeline [2] - The company has successfully launched over 60 approved drugs, including generic drugs, innovative drugs, traditional Chinese medicine, and biological agents [2] - In 2023, the company launched its first innovative drug, Dazisni, approved for the treatment of insomnia, marking a significant milestone in its transformation to an innovation-driven model [2] Revenue Sources - The company's main revenue comes from domestic sales, with total revenue for the years 2023, 2024, and the first ten months of 2025 being approximately RMB 3.999 billion, RMB 4.159 billion, and RMB 3.344 billion respectively [3][5] - Revenue breakdown by business line for 2023 shows that pharmaceutical products contributed RMB 2.326 billion (58.2%), raw materials contributed RMB 956 million (23.9%), and medical devices contributed RMB 637 million (15.9%) [3] Profitability - The gross profit for the years 2023 and 2024 was RMB 1.967 billion and RMB 2.016 billion, respectively, with gross profit margins of 49.2% and 48.5% [5][6] - The net profit for the year 2023 was RMB 623.6 million, with a projected increase to RMB 719.1 million in 2024 [5] Industry Overview - The Chinese pharmaceutical market is expected to grow from RMB 1,447.9 billion in 2020 to RMB 1,629.7 billion by 2024, with a compound annual growth rate (CAGR) of 3.0% [8] - The market for patented drugs is projected to increase its share from 44.6% in 2020 to 70.0% by 2035, while the share of generic drugs is expected to decline from 55.4% to 30.0% over the same period [8] Central Nervous System Market - The global central nervous system drug market is projected to grow from USD 233.7 billion in 2020 to USD 258.8 billion by 2024, with a CAGR of 2.6% [9] - The Chinese market for central nervous system drugs is expected to grow from approximately USD 32.2 billion in 2020 to USD 34.1 billion by 2024, with a CAGR of 1.4% [9] Insomnia Drug Market - The insomnia drug market in China is expected to maintain a size of around USD 1.7 billion from 2020 to 2024, with a negative CAGR of -1.0%. However, it is projected to grow to USD 3.5 billion by 2035, with a CAGR of 7.5% from 2025 to 2035 [11] Cardiovascular Drug Market - The global cardiovascular drug market is expected to grow from USD 115 billion in 2020 to USD 124.6 billion by 2024, with a CAGR of 2.0% [12] - The Chinese cardiovascular drug market is projected to decline from USD 25.5 billion in 2020 to USD 24.9 billion by 2024, but is expected to rebound to USD 36.9 billion by 2035, with a CAGR of 4.1% from 2025 to 2035 [12][13]

Company Overview - Jingxin Pharmaceutical (002020.SZ) is an innovation-driven pharmaceutical group focusing on two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases. The company combines the commercialization of existing products with the continuous advancement of its product pipeline [1][2]. Product Portfolio - The company has shifted its strategic focus on innovative drug development towards central nervous system diseases and cardiovascular and cerebrovascular diseases. Its current product portfolio includes over 60 approved drugs, covering generic drugs, innovative drugs, traditional Chinese medicine, and biological agents [2]. - The generic drug segment is a significant part of the company's product mix, providing stable revenue and broad market coverage to support ongoing innovation investments. The focus is on psychiatric and neurological drugs, as well as cardiovascular and cerebrovascular drugs [2]. - The innovative drugs are central to the company's transformation and long-term growth, prioritizing unmet medical needs with clinical value and commercial potential. In 2023, the company launched a new innovative drug, Dazisni, approved for treating insomnia in China, marking a milestone in its transition to an innovation-driven model [2]. Financial Performance - The company reported revenues of approximately RMB 3.999 billion for the fiscal year 2023, with projections of RMB 4.159 billion for 2024 and RMB 3.344 billion for the ten months ending October 31, 2025 [5]. - The net profit for the fiscal year 2023 was approximately RMB 623 million, with projections of RMB 719 million for 2024 and RMB 629 million for the ten months ending October 31, 2025 [4][5]. - The gross profit margin for the fiscal year 2023 was 49.2%, with slight declines projected to 48.5% in 2024 and 48.3% in 2025 [6]. Industry Overview - The Chinese pharmaceutical market is expected to grow from RMB 1,447.9 billion in 2020 to RMB 1,629.7 billion by 2024, with a compound annual growth rate (CAGR) of 3.0%. By 2035, the market is projected to reach RMB 3,103.4 billion, with a CAGR of 6.5% from 2025 to 2035, surpassing the global CAGR of 5.1% during the same period [8]. - The market share of patented drugs is expected to increase from 44.6% in 2020 to 70.0% by 2035, while the market for generic drugs is projected to grow moderately, with a decline in market share from 55.4% to 30.0% over the same period [8]. Central Nervous System Market - The global central nervous system drug market is entering a stable growth phase, with the market size increasing from USD 233.7 billion in 2020 to USD 258.8 billion by 2024, reflecting a CAGR of 2.6%. The Chinese market is also growing, with an increase from approximately USD 32.2 billion in 2020 to USD 34.1 billion by 2024, and an expected CAGR of 4.1% from 2025 to 2035 [10]. - The insomnia drug market in China is projected to maintain a size of around USD 1.7 billion from 2020 to 2024, with a CAGR of -1.0%. However, it is expected to grow to USD 3.5 billion by 2035, with a CAGR of 7.5% from 2025 to 2035 [12]. Cardiovascular Drug Market - The global cardiovascular drug market is expected to grow from USD 115 billion in 2020 to USD 124.6 billion by 2024, with a CAGR of 2.0%. The Chinese market is projected to decline from USD 25.5 billion in 2020 to USD 24.9 billion by 2024, but is expected to rebound to USD 36.9 billion by 2035, with a CAGR of 4.1% from 2025 to 2035 [13][14].

Summary of the Conference Call for Jinxin Pharmaceutical Industry Overview - Jinxin Pharmaceutical focuses on generic drugs, active pharmaceutical ingredients (APIs), and medical devices, with a strong presence in the CNS and cardiovascular sectors. The impact of centralized procurement has gradually diminished, allowing for stable growth in traditional pharmaceutical business [2][3][5]. Key Points Traditional Pharmaceutical Business - The traditional business includes generic drugs, APIs, and medical devices, with generics being the largest revenue contributor. The company has overcome the pressures from centralized procurement, and major products are expected to maintain steady growth [3][5]. - The integration of APIs and formulations provides cost advantages, and the acquisition of Shenzhen Jufeng has strengthened its position in the medical device market [2][5]. Innovative Drug Development - **Dazaxine (地达西尼)**: A new generation insomnia treatment that avoids safety issues associated with traditional benzodiazepines. It has shown rapid market uptake, with sales reaching 110 million RMB in the first three quarters of 2025, exceeding market expectations. It is expected to experience significant growth in 2026 and 2027 [2][6][8]. - **JX2,201**: A novel small molecule targeting lipid reduction, currently in phase II clinical trials. While it may not contribute significantly to short-term revenue, it has substantial business development (BD) potential and is expected to be a key driver of long-term growth [2][7]. Market Position and Competitive Landscape - Dazaxine competes with three major insomnia treatments, including those from Eisai and Shionogi. Its unique mechanism allows for rapid onset of action and minimal interaction with other medications, making it suitable for patients with multiple comorbidities [6][8]. - Jinxin's small molecule LPA innovation drug has a similar structure to Eli Lilly's drug, which is in phase III trials. If successful, it could enhance Jinxin's market position and BD potential [9]. Future Outlook - The company is expected to maintain steady growth in its traditional business due to the resolution of centralized procurement impacts. The rapid commercialization of Dazaxine and the promising outlook for the small molecule LPA drug contribute to a favorable investment profile [11]. - The potential for significant BD transactions for the LPA drug is highlighted, with upfront payments estimated between 100 to 200 million USD and total deals potentially reaching 2 billion USD [4][11]. Additional Insights - The differences between small molecule and small nucleic acid LPA-targeting drugs lie in their administration methods and mechanisms of action, with no significant efficacy differences reported so far [10]. - The company’s strategic focus on both traditional and innovative drug segments positions it well for future growth and investment opportunities [3][11].

（文章来源：证券日报） 证券日报网讯 1月12日，京新药业在互动平台回答投资者提问时表示，公司在努力推进地达西尼的销售 工作，可以贡献更好的业绩。具体数据敬请关注相关定期报告。 ...

Investment Rating - The report maintains a positive outlook on the insomnia treatment market, highlighting the potential for new drug sales performance in this sector [20][32]. Core Insights - The insomnia treatment market in China is characterized by a significant unmet need, with over 200 million individuals estimated to suffer from insomnia symptoms, representing a large consumer market potential [16][24]. - The report emphasizes the shift towards innovative insomnia medications, particularly focusing on new types of benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs) as key areas for development [25][38]. - The introduction of new drugs like JY-202 (地达西尼) and DORA medications is expected to reshape the market dynamics, with a forecasted rapid increase in market share and sales [34][39]. Market Overview - The insomnia drug market in China has seen stagnant growth due to a lack of new effective treatments, with the market size in 2023 estimated at 31.62 billion yuan [24]. - The report outlines the historical sales performance of major insomnia medications, indicating a long gap since the last new product launch in 2007, which has contributed to the current market stagnation [24][25]. - The report projects a significant increase in the market size and sales for innovative insomnia drugs, particularly with the anticipated approval and market entry of new products [34][39]. Drug Development Trends - The report identifies two main directions for insomnia drug innovation: improvements on existing BZRAs and the development of DORAs, which are expected to have lower addiction risks and better patient compliance [25][38]. - The new drug JY-202 is highlighted for its selective action on the GABAA receptor, which may reduce side effects associated with traditional insomnia medications [34]. - The report also notes the successful clinical trial results for DORAs, which have shown significant improvements in sleep quality without the risk of addiction, making them suitable for broader consumer use [38][39]. Key Players and Recommendations - The report suggests focusing on companies like 京新药业 (JY-202) and 先声药业 (DORA medications) as they are positioned to capitalize on the emerging market opportunities in insomnia treatment [34][39]. - It recommends monitoring the sales performance of these new drugs as they enter the market, particularly in the context of changing consumer behavior and increasing awareness of sleep health [20][32].

Core Viewpoint - The article emphasizes the significant market potential for insomnia treatment, highlighting the promising sales performance of newly listed drugs in this sector [16][22][24]. Market Overview - The current insomnia medication market in China is estimated at 31.62 billion yuan, with a large unmet demand due to existing medications failing to meet treatment needs [26]. - The proportion of individuals experiencing insomnia symptoms in China is reported at 16.8%, indicating a potential patient population exceeding 200 million [20][31]. Drug Development and Innovation - The development of insomnia medications has evolved through four generations, with the latest focusing on physiological regulation rather than merely sedative effects [21][32]. - New insomnia drugs, particularly novel benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs), are gaining traction, with several products recently launched [24][34]. Specific Drug Insights - The newly launched drug, Dazadiline, is expected to capture a significant market share due to its unique mechanism of action and favorable safety profile, with projected peak sales of 15.6 billion yuan [33]. - Dazadiline's pricing is set at 13.88 yuan per day, making it competitive in the market [33]. - DORAs, such as Daridorexant, are noted for their non-addictive properties and potential for broader consumer acceptance, as they do not fall under strict regulatory controls [38]. Market Dynamics - The article discusses the competitive landscape, noting that the introduction of new insomnia treatments could disrupt the existing market dominated by older, less effective medications [26][27]. - The sales performance of insomnia drugs is expected to improve significantly as new products enter the market and address the needs of a large patient population [16][24]. Future Projections - The article forecasts a steady increase in the number of patients treated for insomnia, with the treatment rate projected to rise from 7.5% in 2024 to 12.1% by 2033 [31]. - The market for insomnia medications is anticipated to grow rapidly, driven by the introduction of innovative therapies and an increasing awareness of sleep health [16][24].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 23.54 CNY based on a 22x P/E ratio for 2026 [5][12]. Core Insights - The company is in a rapid growth phase for its core business and key products over the next 1-2 years, with adjustments made to revenue and expense forecasts [5]. - The first innovative drug, Dazisin, has been approved and is expected to perform well commercially, with significant market potential in the insomnia treatment sector [12][42]. - The company has a strong pipeline focusing on central nervous system and lipid-lowering therapies, with promising products in various stages of development [12][22]. Financial Summary - Revenue projections for the company are as follows: - 2023: 3,999 million CNY - 2024: 4,159 million CNY (growth of 4.0%) - 2025: 4,279 million CNY (growth of 2.9%) - 2026: 4,714 million CNY (growth of 10.2%) - 2027: 5,363 million CNY (growth of 13.8%) [7]. - Net profit attributable to the parent company is projected to grow from 619 million CNY in 2023 to 1,079 million CNY in 2027, reflecting a compound annual growth rate of approximately 17.5% [7]. Business Focus - The company has shifted its focus towards innovation after facing challenges from centralized procurement, with a robust pipeline of generic and innovative drugs [12][15]. - The main therapeutic areas include central nervous system disorders, cardiovascular diseases, and digestive system conditions, with a strong emphasis on innovative drug development [15][19]. Product Pipeline - The company has a diverse pipeline with key products such as: - Dazisin (approved for insomnia) - JX11502 (in Phase II for schizophrenia) - JX2201 (in Phase I for high Lp(a) levels) [23][32]. - The company is also pursuing first-generic opportunities for high-value products, such as Calira, which has significant market potential [27][29]. Market Position - The company has established a solid market presence in the CNS and lipid-lowering sectors, with leading market shares in several key products [24][26]. - The innovative drug Dazisin is positioned to capture a significant share of the insomnia treatment market, which has over 200 million patients in China [42][45].

Core Insights - Jingxin Pharmaceutical has achieved hospital coverage of over 1,500 for its drug Didasanib in the first half of the year, indicating a strong market presence and ongoing efforts to enhance patient accessibility [2] Company Summary - The company is actively promoting the hospital admission of Didasanib, which reflects its commitment to improving patient access to this medication [2]

Core Viewpoint - The company is committed to enhancing the sales efforts of its product, Didasyn, aiming to contribute more revenue and profit to the organization [1] Group 1 - The company is actively working to promote the sales of Didasyn [1] - The company expresses its intention to increase revenue and profit through these sales efforts [1]